Oncogene News and Research

RSS

An oncogene is a gene that, when mutated or expressed at high levels, helps turn a normal cell into a tumor cell.

Scientists design synthetic molecule to protect liver cancer cells from toxic effects of chemotherapy

Scientists have found that a synthetic molecule they designed can block activation of a gene in liver cancer cells, halting a process that allows some of those cancer cells to survive chemotherapy.

13 Oct 2010

Novel hormonal treatments may help ER-negative breast cancer patients: Study

Women who have estrogen (ER) negative breast cancer may have more drug treatment options than previously thought, a Creighton (pronounced Cray-ton) University study suggests. The study is reported in the Oct. 11 online version of the journal Oncogene.

11 Oct 2010

Study suggests balance between NF-kB and p53 signaling as a promising target for new cancer drugs

A new report published in the October 2010 print issue of The FASEB Journal offers a ray of hope in the search for new cancer drugs. By examining the seemingly conflicting roles of how oncogenes and tumor suppressor genes handle cellular stress, scientists from the Institute for Advanced Studies in New Jersey argue that each of these opposing systems could be potent drug targets in the effort to stop cancer. In addition, their hypothesis provides new insights into what contributes to immunological disorders such as chronic inflammation and autoimmune diseases.

1 Oct 2010

African-American lung cancer patients with EGFR mutation respond better to erlotinib therapy

African-American patients with non-small cell lung cancer are just as likely to display an epidermal growth factor receptor (EGFR) mutation in tumors as Caucasians, which suggests they are as likely to benefit from targeted therapies such as erlotinib.

29 Sep 2010

Cylene commences CX-4945 Phase I trial in multiple myeloma

Cylene Pharmaceuticals, Inc. announced today the initiation of a Phase I clinical trial of their first-in-class, oral CK2 inhibitor CX-4945 in patients with multiple myeloma. Cylene also announced the simultaneous closing of a $12 million financing with participation from existing investors including Sanderling Ventures, HBM BioVentures (Cayman) Ltd., Novartis BioVenture Fund, BioVentures Investors, Lilly Ventures, Mitsui & Co. and Morningside Venture Investments Ltd.

24 Sep 2010

Researchers discover new signaling pathway for cell development

Researchers at UCLA's Jonsson Comprehensive Cancer Center have discovered a new cell signaling pathway that controls cell growth and development, a pathway that, when defective, helps promote the formation of several major forms of human cancer, including lymphoma and leukemia.

24 Sep 2010

Boehringer Ingelheim commences afatinib Phase III clinical trial in advanced breast cancer

Boehringer Ingelheim today announced the initiation of a phase III clinical trial to investigate one of its most advanced oncology pipeline compounds, afatinib, for the treatment of patients with advanced (metastatic) breast cancer. Afatinib is an oral compound (taken as a tablet), which is a next generation, targeted therapy, that irreversibly inhibits both, the epidermal growth factor receptor (EGFR/HER1) and the human epidermal receptor HER2, which are involved in tumour growth and spread.

18 Sep 2010

Notch1 protein impacts childhood leukemia progression: Study

A protein crucial for the immune response appears to be a key player in the progression of a devastating form of childhood leukemia called T-cell acute lymphoblastic leukemia (T-ALL). Suppressing the activity of the protein kills the leukemic cells, the study shows, opening a potential avenue to new drugs that could prevent progression of the disease.

14 Sep 2010

Advaxis publishes research article on Her2 antigen for Listeria vaccine

Scientists at Advaxis, Inc.,the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, recently had their research using ADXS31-164, a live Listeria vaccine that targets Her2, published in a leading peer reviewed journal (Shahabi, et al 2010 Cancer Gene Therapy epublished ahead of print).

13 Sep 2010

Two genes linked to ovarian clear cell carcinoma

Scientists at the Johns Hopkins Kimmel Cancer Center have identified two genes whose mutations appear to be linked to ovarian clear cell carcinoma, one of the most aggressive forms of ovarian cancer. Clear cell carcinoma is generally resistant to standard therapy.

9 Sep 2010

Scientists discover over-expression of C35 gene in HER2 positive tumours

UK scientists have discovered that a gene called C35 can work together with other cancer-promoting genes to drive the growth and invasion of breast cancer cells in the lab.

9 Sep 2010

Cylene Pharmaceuticals to report recent developments of CX-4945 inhibitor at CK2 International Conference

Cylene Pharmaceuticals, Inc. will report recent developments with its first-in-class, oral CK2 inhibitor CX-4945, at the 6th International Conference on Protein Kinase CK2, to be held on September 7-10 in Cologne, Germany, the company announced today.

9 Sep 2010

ProteaBio concludes agreement with George Washington University to commercialize LAESI technology

ProteaBio Europe SAS, a leading developer of new technology, announced today that the company has concluded an exclusive, worldwide license agreement with George Washington University for commercial rights to a new technology that provides rapid identification of a broad range of chemicals and biomolecules.

8 Sep 2010

Study establishes critical roles for cancer-causing Myc gene in stem cell biology

Stem cells might be thought of as trunks in the tree of life. All multi-cellular organisms have them, and they can turn into a dazzling variety other cells-kidney, brain, heart or skin, for example. One class, pluripotent stem cells, has the capacity to turn into virtually any cell type in the body, making them a focal point in the development of cell therapies, the conquering of age-old diseases or even regrowing defective body parts.

3 Sep 2010

Scientists develop new combined treatment method for skin cancer prevention

Scientists at The University of Texas Health Science Center San Antonio are on to something that should bring joy to sunbathers everywhere. Studies show that certain plant substances, administered in combinations, have the ability to suppress skin cancer development in susceptible mice.

30 Aug 2010

Researchers find new way to study oncogene's role in DNA repair

A key step in understanding the origins of familial breast cancer has been made by two teams of scientists at the University of California, Davis. The researchers have purified, for the first time, the protein produced by the breast cancer susceptibility gene BRCA2 and used it to study the oncogene's role in DNA repair.

23 Aug 2010

Breast cancer accomplice discovered

Scientists have discovered an accomplice in breast cancer - a master control switch with the power to set off a cascade of reactions orchestrated by a cancer-causing gene (or oncogene) named Wnt1. This executive molecule and its modus operandi are reported in back-to-back papers featured on the cover of the August 15 issue of Cancer Research.

18 Aug 2010

Scientists discover new signaling pathway to reduce tumour growth in glioblastoma multiforme

Malignant gliomas are the most common subtype of primary brain tumor - and one of the deadliest. Even as doctors make steady progress treating other types of solid tumor cancers, from breast to prostate, the most aggressive form of malignant glioma, called a glioblastoma multiforme or GBM, has steadfastly defied advances in neurosurgery, radiation therapy and various conventional or novel drugs. But an international team of scientists, headed by researchers at the Ludwig Institute for Cancer Research (LICR) at the University of California, San Diego School of Medicine, reports in the August 15 issue of Genes & Development that they have discovered a new signaling pathway between GBM cells - one that, if ultimately blocked or disrupted, could significantly slow or reduce tumor growth and malignancy.

16 Aug 2010

Astex and MMRC commence Phase II clinical trial of AT7519 CDK inhibitor in multiple myeloma

Astex Therapeutics, the UK-based biotechnology company developing targeted therapies for oncology and virology, and the Multiple Myeloma Research Consortium announced today the initiation of a Phase II clinical trial of the cyclin-dependent kinase inhibitor, AT7519, to treat patients with relapsed or refractory multiple myeloma, an incurable blood cancer. The trial is designed to investigate both single agent and combination activity of AT7519 with bortezomib (Velcade®).

13 Aug 2010

Researchers discover mechanism linking H. pylori infection and stomach cancer

Researchers have discovered a mechanism by which Helicobacter pylori, the only known cancer-causing bacterium, disables a tumor suppressor protein in host cells.The new study, in the journal Oncogene, reports the discovery of a previously unknown mechanism linking H. pylori infection and stomach cancer, the second leading cause of cancer deaths worldwide.

2 Aug 2010

Oncogene News and Research

Further Reading

Scientists design synthetic molecule to protect liver cancer cells from toxic effects of chemotherapy

Novel hormonal treatments may help ER-negative breast cancer patients: Study

Study suggests balance between NF-kB and p53 signaling as a promising target for new cancer drugs

African-American lung cancer patients with EGFR mutation respond better to erlotinib therapy

Cylene commences CX-4945 Phase I trial in multiple myeloma

Researchers discover new signaling pathway for cell development

Boehringer Ingelheim commences afatinib Phase III clinical trial in advanced breast cancer

Notch1 protein impacts childhood leukemia progression: Study

Advaxis publishes research article on Her2 antigen for Listeria vaccine

Two genes linked to ovarian clear cell carcinoma

Scientists discover over-expression of C35 gene in HER2 positive tumours

Cylene Pharmaceuticals to report recent developments of CX-4945 inhibitor at CK2 International Conference

ProteaBio concludes agreement with George Washington University to commercialize LAESI technology

Study establishes critical roles for cancer-causing Myc gene in stem cell biology

Scientists develop new combined treatment method for skin cancer prevention

Researchers find new way to study oncogene's role in DNA repair

Breast cancer accomplice discovered

Scientists discover new signaling pathway to reduce tumour growth in glioblastoma multiforme

Astex and MMRC commence Phase II clinical trial of AT7519 CDK inhibitor in multiple myeloma

Researchers discover mechanism linking H. pylori infection and stomach cancer

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News